| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Sander A Flaum last filed a Form 4 in March 2019, as Director at EGRX. Sander A Flaum's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 13,510 shares of EGRX. The EGRX filings lean toward selling, a net 20,365 shares.
Sander A Flaum has 10 Form 4 filings on record from March 2015 to March 2019, all as Director at Eagle Pharmaceuticals (EGRX), 2015–2019.
The 13 reported transactions were 6 option or other derivative awards, 4 open-market sales, 2 option exercises and 1 tax withholding.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $1.2M.
The largest open-market sale was 13,025 shares of EGRX at an average $54.81 on December 22, 2015, about $714K.
Shares as reported in the last Form 4 for each company; the most recent is from March 2019. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.